Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1975 1
1976 1
1977 1
1978 3
1980 3
1981 1
1982 2
1983 2
1984 1
1985 5
1986 6
1987 8
1988 13
1989 6
1990 8
1991 6
1992 13
1993 7
1994 8
1995 9
1996 7
1997 6
1998 2
1999 3
2000 3
2001 6
2002 9
2003 6
2004 5
2005 3
2006 6
2007 4
2008 9
2009 4
2010 5
2011 8
2012 10
2013 6
2014 10
2015 3
2016 8
2017 8
2018 7
2019 6
2020 11
2021 5
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

250 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Schroeder KW, Tremaine WJ, Ilstrup DM. Schroeder KW, et al. N Engl J Med. 1987 Dec 24;317(26):1625-9. doi: 10.1056/NEJM198712243172603. N Engl J Med. 1987. PMID: 3317057 Clinical Trial.
We assessed oral 5-aminosalicylic acid (5-ASA) prepared with a pH-sensitive polymer coating in 87 patients with mildly to moderately active ulcerative colitis in a double-blind, placebo-controlled trial. ...
We assessed oral 5-aminosalicylic acid (5-ASA) prepared with a pH-sensitive polymer coating in 87 patients with mildly to mode …
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Murray A, et al. Cochrane Database Syst Rev. 2020 Aug 12;8(8):CD000543. doi: 10.1002/14651858.CD000543.pub5. Cochrane Database Syst Rev. 2020. PMID: 32786164 Free PMC article.
BACKGROUND: Oral 5-aminosalicylic acid (5-ASA) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. ...
BACKGROUND: Oral 5-aminosalicylic acid (5-ASA) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) …
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Murray A, et al. Cochrane Database Syst Rev. 2020 Aug 28;8(8):CD000544. doi: 10.1002/14651858.CD000544.pub5. Cochrane Database Syst Rev. 2020. PMID: 32856298 Free PMC article.
BACKGROUND: Oral 5-aminosalicylic acid (5-ASA; also known as mesalazine or mesalamine) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. ...
BACKGROUND: Oral 5-aminosalicylic acid (5-ASA; also known as mesalazine or mesalamine) preparations were intended to avoid the …
Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
Qiu X, Ma J, Wang K, Zhang H. Qiu X, et al. Oncotarget. 2017 Jan 3;8(1):1031-1045. doi: 10.18632/oncotarget.13715. Oncotarget. 2017. PMID: 27906680 Free PMC article. Review.
BACKGROUND AND AIMS: The chemopreventive effect of 5-aminosalicylic acid (5-ASA) in patients with inflammatory bowel disease (IBD) has been widely studied; however, the results remain conflicting. ...
BACKGROUND AND AIMS: The chemopreventive effect of 5-aminosalicylic acid (5-ASA) in patients with inflammatory bowel disease ( …
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK. Wang Y, et al. Cochrane Database Syst Rev. 2016 Apr 21;4(4):CD000543. doi: 10.1002/14651858.CD000543.pub4. Cochrane Database Syst Rev. 2016. PMID: 27101467 Free PMC article. Updated. Review.
BACKGROUND: Oral 5-aminosalicylic acid (5-ASA) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. ...
BACKGROUND: Oral 5-aminosalicylic acid (5-ASA) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) …
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Wang Y, Parker CE, Feagan BG, MacDonald JK. Wang Y, et al. Cochrane Database Syst Rev. 2016 May 9;2016(5):CD000544. doi: 10.1002/14651858.CD000544.pub4. Cochrane Database Syst Rev. 2016. PMID: 27158764 Free PMC article. Updated. Review.
BACKGROUND: Oral 5-aminosalicylic (5-ASA) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. ...
BACKGROUND: Oral 5-aminosalicylic (5-ASA) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maint …
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Sutherland L, Macdonald JK. Sutherland L, et al. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD000543. doi: 10.1002/14651858.CD000543.pub2. Cochrane Database Syst Rev. 2006. PMID: 16625536 Updated. Review.
OBJECTIVES: To assess the efficacy, dose-responsiveness and safety of the newer release formulations of 5-aminosalicylic acid (5-ASA) compared to placebo or sulfasalazine (SASP) for the induction of remission in active ulcerative colitis. ...However, considering the …
OBJECTIVES: To assess the efficacy, dose-responsiveness and safety of the newer release formulations of 5-aminosalicylic acid …
250 results

Searches related to "aminosalicylic acid"